Alain Fischer

from Wikipedia, the free encyclopedia

Alain Fischer (born September 11, 1949 in Paris ) is a French medic. In particular, he researched congenital immune deficiencies and their gene therapy treatment.

Fischer received his diploma and doctorate in medicine from the University of Paris VII in 1979 . He is Professor of Pediatric Immunology at the University of Paris V ( University of Paris Descartes ) and at the Institut universitaire de France . Since 1996 he has also been head of the pediatric immunology department at the Hôpital Necker-Enfants malades in Paris. Since 1991 he has been head of the INSERM group Normal and Pathological Development of the Immune System ( Développement normal et pathologique du système immunitaire ).

In 1999, with Marina Cavazzana-Calvo, he achieved the first successful clinical gene therapy for a congenital immune deficiency. However, two of the children developed leukemia because a proto-oncogene was inadvertently incorporated into the gene therapy . The study was therefore temporarily discontinued.

In 1998 he received the Ernst Jung Prize and in 2001 in Geneva the Prix ​​Louis-Jeantet in Medicine. In 2008 he received the Grand Prix of INSERM ( Institut national de la santé et de la recherche médicale ) and in 2012 the Avery Landsteiner Prize . For 2014 he was awarded the Robert Koch Prize and for 2015 the Japan Prize . He is a member of the Académie des sciences (2002), the Académie nationale de Médecine (2011), the European Molecular Biology Organization (EMBO, 2002), the Academia Europaea (2009) and the National Academy of Sciences (2019). In 2010 he became an officer of the Legion of Honor . From 2003 to 2009 he was on the French national ethics council. In 2015 he received an honorary doctorate from Ulm University .

Web links

Individual evidence

  1. Cavazzana-Calvo, Fischer et al. a. Gene Therapy of human severe combined immunodeficiency (SCID) -X1 Disease , Science, Volume 288, 2000, pp. 669-672
  2. Fischer u. a .: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1., Science, Volume 302, 2003, pp. 415-419, PMID 14564000